INS and type 1 diabetes mellitus: Furthermore, a recently completed phase III clinical trial (PROTECT) of children and adolescents with new-onset T1D has confirmed these earlier findings on C-peptide preservation at 18 months after enrolment and suggested improvements in insulin use, continuous glucose metrics, hypoglycaemia and patient reported outcomes203.